Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), has shown promise in addressing these comorbidities, offering potential benefits in obesity-related HFpEF. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.